Where to buy dca cancer

We appreciate your feedback and encouragement. We would also like to acknowledge and extend a special thanks to two of our patients who brought DCA to our attention, and motivated us to begin DCA treatments. This is greater than the sum of all patients in all of the human DCA clinical trials that have ever been conducted both cancer and non-cancer put together! Even though we are not conducting a clinical trial, the experience gained by treating such a large number of patients is extraordinary, and helps us to use DCA more safely and effectively.

In it was discovered that the drug DCA dichloroacetate sodium induced the death of human breast, lung and brain cancer cells that were implanted into rats, while being non-toxic to healthy cells. This research was published in Cancer Cell, 11, 37—51, January DCA has been found to kill cancer cells by a newly discovered mechanism that appears to be common to several types of cancer.

DCA works by turning on the natural cell suicide system called apoptosis which is suppressed in cancerous cells, thus allowing them to die on their own. DCA does not poison the cells like cytotoxic chemotherapy drugs.

At the same time, it does not starve healthy cells in the body of glucose. DCA research has accelerated in the last 2 years. The latest research shows that DCA also kills many types of cancer cells, and can boost the cancer-killing effects of radiation. The first formal human cancer research using DCA was published in May This database can be searched free of charge for those interested in reading DCA research, or at least the summaries of the DCA publications: here.

Further research to determine how well DCA works against various cancers within the human body is ongoing: here. Several publications demonstrate that DCA works in a variety of cancers. For the first time in the world, on Dec 7, we publicly shared our observational data from the treatment of our first cancer patients with DCA. We updated our data in from treating over patients. Since clinical trial data is now emerging, we are no longer collecting observational data.

Instead, we are focusing our efforts on publishing our findings in reputable peer reviewed medical journals. Our DCA publications can all be viewed here. We have other DCA papers currently being written and we hope to continue publishing in the future. DCA is a synthetic drug, but it is a very simple compound similar to a chemical combination of salt and vinegar. It works against cancer in a natural way by triggering natural cell suicide. Our experience so far suggests that DCA is safe to use in cancer patients under close medical supervision.

Some animal studies show that DCA can itself cause liver cancer. These studies used doses which are much higher than what would be prescribed for cancer treatment. Also, no human study has every demonstrated liver tumour formation as a result of DCA therapy. We have observed that DCA can have 2 main categories of side effects.

Neuropathy typically takes several weeks to months to develop, and is reversible if it is caught early. In the existing literature, neuropathy from DCA has always been shown to be reversible. We use vitamin B1 benfotiamine or thiamine , acetyl L-carnitine and R alpha lipoic acid to prevent and reduce the severity of peripheral neuropathy.

These medicines can be given orally or intravenously depending on the degree of neuropathy. Sedation, confusion, hallucinations, memory problems, mood changes, hand tremors. These side effects are temporary and appear to be dose-dependent and age-dependent. This finding is consistent with existing human research on DCA that we have reviewed.

If you are a Medicor patient, you will receive our latest dosing guidelines for these supplements. Due to potential interference with other ongoing treatments like radiation or chemotherapy, certain supplements may not be recommended, or may have to be skipped during part of the radiation or chemo treatment. Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl Biochem Biophys Res Commun. Mol Cancer Ther.

J Am Soc Nephrol. Time-programmed DCA and oxaliplatin release by multilayered nanofiber mats in prevention of local cancer recurrence following surgery. J Control Release. Sodium dichloroacetate DCA reduces apoptosis in colorectal tumor hypoxia. Cancer Lett. DCA promotes progression of neuroblastoma tumors in nude mice. Am J Cancer Res. Effect of dichloroacetate on Lewis lung carcinoma growth and metastasis.

Exp Oncol. Dichloroacetate at therapeutic concentration alters glucose metabolism and induces regulatory T-cell differentiation in alloreactive human lymphocytes. J Basic Clin Physiol Pharmacol. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity.

Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. Non-Hodgkin's Lymphoma Reversal with Dichloroacetate. J Oncol. Epub Sep Peripheral neuropathy in rats exposed to dichloroacetate. Yu, S. Borgel et al. Stacpoole, N. Nagaraja, and A. View at: Google Scholar P. Michelakis, G. Sutendra, P. Dromparis et al. Stacpoole, C. Martyniuk, M. James, and N. Felitsyn, P. Stacpoole, and L. Langaee, R. Wagner, L. Horne et al. Brandsma, T. Dorlo, J. Haanen, J. Beijnen, and W. Lu, D.

Zhou, B. Hou et al. Korga, M. Ostrowska, M. Iwan, M. Herbet, and J. Sun, A. Zhu, X. Zhou, and F. Woolbright, D. Choudhary, A. Mikhalyuk et al. Fekir, H. Dubois-Pot-Schneider, R. Aleksander-Krasko, V. Verma, Y. Lam, Y. Leung et al. Li, X. Li, H. Xiong et al. Lucido, W. Miskimins, and P. Abildgaard, C. Dahl, A. Abdul-Al, A. Christensen, and P. Prokhorova, O. Pyaskovskaya, D. Kolesnik, and G. View at: Google Scholar D. Kolesnik, O. Pyaskovskaya, Y.

Yakshibaeva, and G. View at: Google Scholar W. Jiang, S. Finniss, S. Cazacu et al. Waltenberger, A. Mocan, K. Heiss, A. Atanasov, and A. Zadorozhna, T.

Tataranni, and D. Della Sala, F. Mazzoccoli, T. Tataranni, V. Costantino, and C. Atanasov, B. Waltenberger, E. Pferschy-Wenzig et al. Sporn and N. Singh, J. George, and N. Redondo-Blanco, J. Villar, and F. Aggarwal, A.

Kumar, and A. Kan, Y. Chang, C. Chien, C. Su, and H. Hata, K. Hori, H. Ogasawara, and S. Dehelean, S. Feflea, J. Zupko, and C. View at: Google Scholar M. Drag, P. Surowiak, M. Drag-Zalesinska, M. Dietel, H. Lage, and J. Mihoub, A. Pichette, B. Sylla, C. Gauthier, and J. Wang, H. Jiang, M. Van De Gucht, and M. Pouget, S. Frelon, J. Ravanat, I. Testard, F.

Odin, and J. Rycaj and D. Tang, F. Wei, Y. Wu et al. Xie, Y. Liu, Q. Yao et al. Zhang and S. Jiang, H. Wang, and M. Niewisch, Z. Wolburg et al. Pitroda, B. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics ;— Potent effects of dioscin against pancreatic cancer via miRP-mediated inhibition of the Akt1 signalling pathway. Br J Pharm. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD, dichloroacetate, and radicicol.

Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS J. Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype. Stacpoole PW. The pharmacology of dichloroacetate. Metab: Clin Exp. Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity. J Pharmacol Exp Therap. Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism.

Exp Cell Res. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Kimmelman AC, White E. Autophagy and tumor metabolism.

Cell Metab ;— Diversity of the pyruvate dehydrogenase kinase gene family in humans. J Biol Chem. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab. Cell Death Differ. The genetics of the p53 pathway, apoptosis and cancer therapy.

Nat Rev Drug Discov. The p53 tumor suppressor in the control of metabolism and ferroptosis. Front Endocrinol. Contractor T, Harris CR. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. Cancer's molecular sweet tooth and the Warburg effect. Poly ADP-ribose polymerase 1 is necessary for coactivating hypoxia-inducible factordependent gene expression by Epstein-Barr virus latent membrane protein 1.

PLoS Pathog. Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia. Download references. Ningbo Aitagene Technology Co. LTD, Shanghai, China. You can also search for this author in PubMed Google Scholar.

Reprints and Permissions. Liang, Y. Oncogene 39, — Download citation. Received : 16 March Revised : 17 September Accepted : 19 September Published : 09 October Issue Date : 09 January Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Journal of Translational Medicine BMC Cancer Oncogenesis Advanced search. Skip to main content Thank you for visiting nature. Download PDF. Abstract The development of chemoresistance remains a major challenge that accounts for colorectal cancer CRC lethality.

Full size image. Discussion CRC is characterized by tumorigenic abnormalities and altered metabolic pathways and is one of the leading causes of death from cancers [ 2 ]. Statistical analysis Data were analyzed by GraphPad Prism 6.

References 1. Google Scholar 3. PubMed Google Scholar 4.